BioVendor:FGF21 ELISA 試劑盒

成纖維細胞生長因子21( fibroblast growth factor 21，FGF21) 屬于成纖維細胞生長因子家族FGF19( fibroblast growth factor 19，FGF19) 的亞型，不具有促成纖維細胞生長活性，且不與肝素特異性結合，是一種調節機體代謝的分泌型蛋白。在骨骼肌、腎臟、心臟以及血管和脂肪組織中 fgf21 表達比肝臟中高約 7～10 倍。FGF21可靶向腦、心臟、骨骼肌以及腎臟和腸等多種組織器官發揮作用。近來證實，FGF21 已廣泛應用于肝脂、糖脂代謝以及心血管疾病等代謝性疾病的預防與康復，可能成為代謝性疾病預防和康復的有效靶點之一。

作為專業的生命科學醫藥原料供應商，艾美捷科技為您推薦BioVendor榮譽產品，FGF21 ELISA 試劑盒！

* BioVendor榮譽出品..僅供科研使用，不得用于醫療.

FGF21-human ELISA Kit 標曲

更多人類樣本FGF21參考資料：點擊下載PDF

FGF21 ELISA 產品已發表文章：

• Ahola S, Auranen M, Isohanni P, Niemisalo S, Urho N, Buzkova J, Velagapudi V, Lundbom N, Hakkarainen A, Muurinen T, Piiril? P, Pietil?inen KH, Suomalainen A.Modified Atkins diet induces subacute selective ragged-red-fiber lysis inmitochondrial myopathy patients. EMBO Mol Med. 2016 Nov 2;8(11):1234-1247.

• Bisgaard A, S?rensen K, Johannsen TH, Helge JW, Andersson AM, Juul A.Significant gender difference in serum levels of fibroblast growth factor 21 inDanish children and adolescents. Int J Pediatr Endocrinol. 2014;2014(1):7.

• BonDurant LD, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR, Walsh SA,Ornitz DM, Potthoff MJ. FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. Cell Metab. 2017 Apr 4;25(4):935-944.e4.

• Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, Ding X,Elmquist JK, Takahashi JS, Mangelsdorf DJ, Kliewer SA. FGF21 regulates metabolismand circadian behavior by acting on the nervous system. Nat Med. 2013Sep;19(9):1147-52.

• Crooks DR, Natarajan TG, Jeong SY, Chen C, Park SY, Huang H, Ghosh MC, TongWH, Haller RG, Wu C, Rouault TA. Elevated FGF21 secretion, PGC-1α and ketogenicenzyme expression are hallmarks of iron-sulfur cluster depletion in humanskeletal muscle. Hum Mol Genet. 2014 Jan 1;23(1):24-39.

• Cuevas-Ramos D, Almeda-Valdes P, Gómez-Pérez FJ, Meza-Arana CE, Cruz-Bautista I, Arellano-Campos O, Navarrete-López M, Aguilar-Salinas CA. Daily physicalactivity, fasting glucose, uric acid, and body mass index are independent factorsassociated with serum fibroblast growth factor 21 levels. Eur J Endocrinol. 2010 Sep;163(3):469-77.

• Cuevas-Ramos D, Almeda-Valdés P, Meza-Arana CE, Brito-Córdova G, Gómez-PérezFJ, Mehta R, Oseguera-Moguel J, Aguilar-Salinas CA. Exercise increases serumfibroblast growth factor 21 (FGF21) levels. PLoS One. 2012;7(5):e38022.

• Dostálová I, Haluzíková D, Haluzík M. Fibroblast growth factor 21: a novelmetabolic regulator with potential therapeutic properties in obesity/type 2diabetes mellitus. Physiol Res. 2009;58(1):1-7. Review.

• Dostálová I, Kaválková P, Haluzíková D, Lacinová Z, Mráz M, Papezová H,Haluzík M. Plasma concentrations of fibroblast growth factors 19 and 21 inpatients with anorexia nervosa. J Clin Endocrinol Metab. 2008 Sep;93(9):3627-32.

• Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growthfactor-21 may mediate growth hormone resistance in anorexia nervosa. J ClinEndocrinol Metab. 2010 Jan;95(1):369-74.

• Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS,Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistantstate. Diabetes. 2010 Nov;59(11):2781-9.

• Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, Kharitonenkov A, Schuppan D, Flier JS, Maratos-Flier E. Fibroblast growth factor 21 limitslipotoxicity by promoting hepatic fatty acid activation in mice on methionine andcholine-deficient diets. Gastroenterology. 2014 Nov;147(5):1073-83.e6.

• Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, Domingo P, Giralt M, FrühbeckG, Villarroya F. Opposite alterations in FGF21 and FGF19 levels and disturbedexpression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond). 2015 Jan;39(1):121-9.

• Gariani K, Drifte G, Dunn-Siegrist I, Pugin J, Jornayvaz FR. Increased FGF21plasma levels in humans with sepsis and SIRS. Endocr Connect. 2013 Sep17;2(3):146-53.

• Guasti L, Silvennoinen S, Bulstrode NW, Ferretti P, Sankilampi U, Dunkel L.Elevated FGF21 leads to attenuated postnatal linear growth in preterm infantsthrough GH resistance in chondrocytes. J Clin Endocrinol Metab. 2014Nov;99(11):E2198-206.

• Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, Moon MK, Lee HK, Kang SW, Han DS, Kim YB, Jang HC, Park KS. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renaldisease patients receiving long-term peritoneal dialysis. Metabolism. 2010Nov;59(11):1656-62.

• Hero M, Dunkel L, Vaaralahti K, Raivio T. Serum FGF21 in boys with idiopathic short stature: relationship to lipid profile, onset of puberty and growth. ClinEndocrinol (Oxf). 2011 Jul;75(1):141-2.

• Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T,Nielsen S, Pedersen BK. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes. 2009 Dec;58(12):2797-801.

• Chen H, Lu N, Zheng M. A high circulating FGF21 level as a prognostic markerin patients with acute myocardial infarction. Am J Transl Res. 2018 Sep15;10(9):2958-2966. eCollection 2018.

• Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulatingfibroblast growth factor 21 is induced by peroxisome proliferator-activatedreceptor agonists but not ketosis in man. J Clin Endocrinol Metab. 2009Sep;94(9):3594-601

• Jian WX, Peng WH, Jin J, Chen XR, Fang WJ, Wang WX, Qin L, Dong Y, Su Q.Association between serum fibroblast growth factor 21 and diabetic nephropathy.Metabolism. 2012 Jun;61(6):853-9.

• Jin QR, Bando Y, Miyawaki K, Shikama Y, Kosugi C, Aki N, Funaki M, Noji S.Correlation of fibroblast growth factor 21 serum levels with metabolic parametersin Japanese subjects. J Med Invest. 2014;61(1-2):28-34.

BioVendor是歐洲的一家生物醫藥科技公司, 總部位于捷克共和國布爾諾，專注于為分子和細胞學實驗室提供體外研究產品，主要產品有重組蛋白、抗體和ELISA試劑盒。產品主要應用領域包括：能量代謝和體重調節、骨代謝、心血管疾病和腎病、感染和發炎、鐵代謝研究、肌肉生長調控、神經組織損傷標志物、腫瘤學、胰腺調節分子、分泌型磷脂酶A2等

看到這兒，您心動了嗎？馬上聯系小艾吧！